Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | HAT1 | O14929 | 3/20 | 0.34 |
| ▸ | EP300 | Q09472 | 3/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6621908 | 1.00 | SLC2A1 (0.49) | SLC2A1NR3C1PGRNR3C2AR | |
| SCHEMBL6618356 | 1.00 | SLC2A1 (0.49) | SLC2A1NR3C1PGRNR3C2AR | |
| SCHEMBL6619599 | 0.90 | SLC2A1 (0.52) | SLC2A1NR3C1PGRNR3C2AR | |
| SCHEMBL6621344 | 0.90 | SLC2A1 (0.51) | SLC2A1NR3C1PGRNR3C2AR | |
| SCHEMBL6626077 | 0.86 | SLC2A1 (0.48) | SLC2A1NR3C1PGRNR3C2AR | |
| SCHEMBL6620238 | 0.86 | SLC2A1 (0.48) | SLC2A1NR3C1PGRNR3C2AR | |
| SCHEMBL6620235 | 0.86 | SLC2A1 (0.48) | SLC2A1NR3C1PGRNR3C2AR | |
| SCHEMBL6618769 | 0.85 | SLC2A1 (0.47) | SLC2A1NR3C1PGRNR3C2AR | |
| SCHEMBL6618499 | 0.83 | SLC2A1 (0.48) | SLC2A1NR3C1PGRNR3C2AR | |
| SCHEMBL6620305 | 0.81 | SLC2A1 (0.42) | SLC2A1NPSR1MEN1KMT2AP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818655-B2 | 2-AMINOQUINOLINES; CARDIOVASCULAR, GASTROINTESTINAL, PYSCHOLOGICAL, RESPIRATORY AND NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2004-11-16 | — | — | US | claimed |
| EP-1359915-A4 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM (US) | 2004-07-21 | — | — | EP | claimed |
| US-20040063757-A1 | Urotensin-ll receptor antagonists | SMITHKLINEE BEECHAM CORPORATION | 2004-04-01 | — | — | US | claimed |
| EP-1359915-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | Smithkline Beecham (US) | 2003-11-12 | — | — | EP | claimed |
| WO-2002058702-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (GB) | 2002-08-01 | — | — | WO | claimed |
| US-6818655-B2 | 2-AMINOQUINOLINES; CARDIOVASCULAR, GASTROINTESTINAL, PYSCHOLOGICAL, RESPIRATORY AND NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2004-11-16 | — | — | US | disclosed |
| EP-1359915-A4 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20040063757-A1 | Urotensin-ll receptor antagonists | SMITHKLINEE BEECHAM CORPORATION | 2004-04-01 | — | — | US | disclosed |
| EP-1359915-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | Smithkline Beecham (US) | 2003-11-12 | — | — | EP | disclosed |
| WO-2002058702-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (GB) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063757-A1 | Urotensin-ll receptor antagonists | UTS2R, PLAUR, SCTR | SLC2A1 3284/4885NR3C1 3035/4885PGR 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.